The U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation to EB-101,  Abeona Therapeutics’ treatment for the inherited skin disease epidermolysis bullosa, or EB. Importantly, the designation also covers a severe form of the blistering and open-wound disorder known as recessive dystrophic epidermolysis bullosa, or RDEB. The FDA…
News
Recent Posts
- Placental vesicles may calm chronic inflammation in RDEB, study shows
- Study suggests JEB treatment could be tailored to specific mutation
- Why I refer to EB as a rare skin condition rather than a disease
- Clinic in Florida is first in Southeast to offer gene therapy for fragile skin
- Fiber supplements don’t cut laxative use in children with severe EB